FDA Approval Alert: The Need-to-Know | Remestemcel-L in Pediatric Steroid-Refractory Acute GVHD

In December 2024, the FDA approved remestemcel-L-rknd for pediatric patients 2 months and older with steroid-refractory acute graft versus host disease.

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.
FDA Approves Remestemcel-L in Pediatric SR-aGVHD
Article
Dec 18, 2024 10:13 PM
Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.